UnknownPhase 2psilocybin

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Sponsored by Sheppard Pratt Health System

NCT ID
NCT04433845
Target Enrollment
15 participants
Start Date
2021-03-01
Est. Completion
2023-04-15

About This Study

The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.

Conditions Studied

Treatment Resistant Depression

Interventions

  • •Psilocybin

Eligibility

Age:18 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Diagnosis of Type 2 Bipolar Disorder (BP-II) Depression

Exclusion Criteria:

* Comorbidities

Study Locations (1)

Sheppard Pratt
Baltimore, Maryland, United States

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. | Huxley